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ABSTRACT
In the current article, we provide in vitro efﬁcacy evaluation of a unique accelerator-based neutron source, con-
structed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron cap-
ture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and
V79 cells were incubated and irradiated in various concentrations of boric acid with epithermal neutrons for 2–3
h in a plexiglass phantom, using 2.0 MeV proton energy and 1.5–3.0 mA proton current, resulting in a neutron
ﬂuence of 2.16 × 1012 cm−2. The survival curves of cells loaded with boron were normalized to those irradiated
without boron (to exclude the inﬂuence of the fast neutron and gamma dose components) and ﬁt to the linear–
quadratic (LQ) model. Colony formation assays showed the following cell survival rates (means ± SDs): CHO-
K1: 0.348 ± 0.069 (10 ppm), 0.058 ± 0.017 (20 ppm), 0.018 ± 0.005 (40 ppm); V79: 0.476 ± 0.160 (10 ppm),
0.346 ± 0.053 (20 ppm), 0.078 ± 0.015 (40 ppm); and U251MG: 0.311 ± 0.061 (10 ppm), 0.131 ± 0.022 (20
ppm), 0.020 ± 0.010 (40 ppm). The difference between treated cells and controls was signiﬁcant in all cases
(P < 0.01) and conﬁrmed that the neutron source and irradiation regimen were sufﬁcient for control over cell
colony formation. We believe our study will serve as a model for ongoing in vitro experiments on neutron cap-
ture therapy to advance in this area for further development of accelerator-based BNCT into the clinical phase.
Keywords: boron neutron capture therapy; accelerator-based neutron source; lithium target; boric acid; in vitro
efﬁcacy evaluation
INTRODUCTION
Boron neutron capture therapy (BNCT) is a unique radiotherapy
method based on the interaction of a stable 10B isotope with ther-
mal neutrons. The boron neutron capture reaction (10B(n,α)7Li)
results in the release of high linear energy transfer (high-LET) alpha
and 7Li particles, which destroy tumor cell DNA. Selective accumu-
lation of 10B in cancer cells provides for speciﬁc elimination, while
sparing normal tissues [1], as the penetration of alpha-particles and
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Li nuclei does not exceed single tumor cell depths. Thus, BNCT, in
its ideal application, can provide curative treatment for invasive can-
cers, such as glioblastoma. The efﬁcacy of BNCT from a nuclear
reactor neutron source has been conﬁrmed for certain malignancies,
including glioma [2–4], malignant melanoma [5], and head and
neck cancer [6–9]. However, safety issues, as well as the negative
publicity surrounding the Fukushima accident, turned the world
BNCT community towards development of accelerator-based neu-
tron sources to replace nuclear reactors in both trials and therapy.
Recently, several accelerators destined for hospital placement
have been introduced [10]. For BNCT purposes, a proton acceler-
ator with vacuum insulation and a lithium target have been devel-
oped at the Budker Institute of Nuclear Physics (BINP) at the
Russian Academy of Sciences (Novosibirsk, Russian Federation)
[11]. To the best of our knowledge, no similar accelerator speciﬁc-
ally designed for BNCT has ever been created with such unique fea-
tures. In vitro experiments using tumor and normal cells are
typically carried out at the initial biological efﬁcacy evaluation stage.
It is within this stage that the main contrast to standard radiother-
apy is seen, because BNCT efﬁcacy depends not only on the irradi-
ation source, but also on the accumulation of a boron-containing
agent, whose concentration in tumor cells directly inﬂuences the
treatment effect. In previous experiments at the nuclear reactor,
boric acid was used as a standard boron compound for reliable
intracellular boron concentration [1].
Any proposed replacement for traditional reactor-based therapies
requires pioneering in vitro studies to establish optimum dosages
and cellular effects. Therefore, in the current study, we evaluated
the efﬁcacy of our accelerator-based neutron source using U251MG,
CHO-K1 and V79 cells incubated and irradiated in a boric acid–
containing medium at various boron concentrations (0, 10, 20 and
40 ppm), with absorbed dose calculations and further cell survival
evaluation using a colony-formation assay (CF assay). Such a meth-
od was intentionally used to assure continuous maintenance of bor-
on concentrations during the entire irradiation period, which is one of
the key points of these experiments (compared with reports [27–29]
for other compounds, where boron was not evenly distributed in the
medium and the cells). This study is one of the initial steps of a pro-
ject on synthesis and evaluation of complex boron/high-Z element
compounds for absorbed dose estimation and tumor localization dur-
ing accelerator-based BNCT.
MATERIALS AND METHODS
Cell lines
Human glioma (U251MG) cells, Chinese hamster ovary cells
(CHO-K1), and Chinese hamster lung ﬁbroblasts (V79) were pur-
chased from the Institute of Cytology of the Russian Academy of
Sciences (St Petersburg, Russian Federation), cultured in Iscove’s
modiﬁed Dulbecco’s medium (IMDM) (SIGMA 17633 with L-
glutamine and 25 mH HEPES, without sodium bicarbonate), sup-
plemented with 10% fetal bovine serum (Thermo Scientiﬁc
HyClone SV30160.03 HyClone UK Ltd) and maintained at 37°C
in an atmosphere of 5% CO2.
Boric acid application
In vitro experiments were performed at the Institute of Molecular
and Cell Biology (Novosibirsk, Russian Federation). The cells were
incubated for 2 h in a medium containing boric acid (Sigma-
Aldrich, Inc., St Luis, MO, USA) in various concentrations (10, 20
and 40 ppm) of 10B. The cells without boron were irradiated and
used as controls. At the indicated time points, medium with boric
acid was removed separately for each sample, the cells were washed
with phosphate-buffered saline (PBS), trypsinized (0.05% trypsin-
EDTA, Nacalai Tesque, Inc., Kyoto, Japan), counted and placed in
2 ml plastic vials in the boric acid–containing medium they were
incubated in with the corresponding 10B concentrations (Fig. 1A).
Neutron irradiation
The samples were placed in a phantom made of organic glass at a
depth of 3 cm [12, 13] (Fig. 1B) and irradiated in a tandem acceler-
ator with vacuum insulation (Fig. 2A), with the epithermal neutron
Fig. 1. The samples in 2 ml vials (A) placed in the plexiglass phantom (B).
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beam under the lithium target (Fig. 2B). The irradiation lasted 2–3
h with the following accelerator settings: 2.0 MeV proton energy,
1.5–3.0 mA proton current (providing an epithermal neutron ﬂux
up to 3 × 108 cm−2 s−1). The settings were adjusted to produce
epithermal neutrons eligible for phantom penetration with subsequent
energy decrease to maximize neutron capture by boron in the samples.
The necessary depth of the plexiglass in the phantom between the tar-
get and the cells was estimated using the Monte Carlo method and
provided the maximum thermal neutron irradiation of the samples.
The neutron ﬂux was measured by a detector with a lithium-
containing scintillator (GS20, Saint-Gobain Crystals, Hiram, OH,
USA). Neutron ﬂuence was measured by activation of the gold foil.
Colony-formation assay
After the irradiation, the cells were immediately counted, diluted
and seeded into 6 cm dishes for CF assay. After 1–2 weeks, the
dishes were washed with PBS, ﬁxed with glutaraldehyde, stained
with crystal violet, and dried. Colonies of 50 cells or more were
counted for each sample. Cell survival fractions were calculated
according to a previously adapted protocol [14, 15]. The results
were normalized to controls, which were irradiated without boric
acid to smooth the inﬂuence of concomitant fast neutrons and
gamma-rays, and the statistical signiﬁcance was evaluated using one-
way analysis of variance (ANOVA).
Radiobiological parameters evaluation
The cell survival data were ﬁt to the linear–quadratic (LQ) model,
using the SOLVER add-on in Microsoft Excel. As the issue of the
absorbed dose evaluation in the accelerator-based BNCT remains
controversial, we used the boron concentration instead of the dose
to calculate the radiobiological parameters. Using α′ and β′ values,
the boron concentration needed to control 90% of cell growth, C10
(instead of D10), was calculated by solving the following quadratic
equation:
α β′ + ′ + ( ) =C C ln SF 0,2
where C represented 10B concentration in cells, and in cases with
linear survival curves (where β′ = 0) equaled ln(SF)/α′, otherwise:
′ ′ ′
′
α α β
β
= − ± − ( )C ln SF4
2
;
2
positive values of C were used.
RESULTS
Colony-formation assay
Three types of cells were incubated in boric acid in four different
boron concentrations, which resulted in the analysis of ﬁve samples
for each cell line in each experiment. The dosages chosen were eval-
uated as the most likely, realistic concentrations that could be
reached in a therapeutic situation. Dishes with stained colonies of
each cell line after irradiation with boric acid in the various concen-
trations are shown in Fig. 3. The number of colonies in all cell lines
decreased with increase in boron concentration, with the maximum
effect at 40 ppm. Cell survival rates (means ± SDs) are presented in
Table 1, and the survival curves are plotted in Fig. 4. The difference
between the treated cells and the controls was signiﬁcant in all cases
(P < 0.01). This data shows the dosage-dependent effect of boron
on the neutron beam and that physiologically relevant concentra-
tions can produce a therapeutic effect.
Radiobiological parameters
The calculated parameters are summarized in Table 2. In two of
three cell lines (CHO-K1 and U251MG) β‘ = 0, reﬂecting a linear
decrease in cell survival (typical with high-LET irradiation). In the
V79 cell line, both α‘ and β‘ parameters were present, showing dif-
ferent responses of the cell line to similar irradiation regimens. C10
values reﬂected the sensitivity of the cells loaded with boron to
Fig. 2. The accelerator-based neutron source at the Budker Institute of Nuclear Physics, Russian Academy of Sciences (A).
The plexiglass phantom set up under the lithium target (B).
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neutron irradiation. This indicates that BNCT would therefore be
useful for multiple types of treatments.
DISCUSSION
Recently, a surge in medical interest has seen the development of
accelerator-based neutron sources all over the world to replace reac-
tors (for safety and accessibility reasons) [10]. To this end, several
types of neutron-producing targets have been introduced: solid 7Li
(p,n) [16], Be(p,n) [17], 9Be(d,n) [18] and liquid 7Li(p,n) [19].
With this in mind, a team of physicists at BINP has developed a
compact tandem accelerator with vacuum insulation and a lithium
target, which might have certain advantages over other materials in
terms of the number and spectrum of neutrons produced [11].
Initially, in 1998 Bayanov et al. reported on neutrons produced as a
result of a threshold reaction involving 7Li(p,n)7Be after application
of a proton beam of 2–2.5 MeV and 10 mA on a lithium target
[20]. Further development of the lithium target and the results of
the neutron spectrum analysis were reported [21]. The ﬁrst
experimental results of neutron production using a 2 MeV-proton
tandem accelerator with vacuum insulation were shown in 2008
[22]. Bayanov et al. have reported on neutron generation experi-
ments on a new 2MeV tandem accelerator using a specially
designed lithium target [23, 24]. It was only then that radiobio-
logical experiments became available (after stabilization of the pro-
ton current to 1.5–2 mA was achieved [25] and the size of the
accelerator was reduced to make it more compact [26]). It is within
this framework of rapid development that we conducted our initial
studies to investigate the efﬁcacy of accelerator-based neutron
sources.
To date, initial radiobiological experiments on tumor cells to
evaluate the efﬁcacy of the neutron source at BINP have been per-
formed with L-p-boronophenylalanine (BPA) [27–29], a boron
agent. This compound was previously used as a 10B compound in
clinical trials in reactor-based BNCT, along with disodium mercap-
toundecahydrododecaborate (BSH) [30, 31]. However, the results
of such in vitro experiments highlighted a critical point; namely, that
cellular boron accumulation depends on transport mechanisms and
can be inﬂuenced by a number of factors, creating the necessity to
search for ways to optimize cellular boron levels at those needed for
therapy [32]. Such variations in boron compound accumulation can
signiﬁcantly alter the results of a treatment. Further trials might be
needed to establish baseline values and reliably predict clinical
outcomes.
The reliability of boric acid has been proven in a previously
reported radiobiological dosimetry study at the reactor-based neu-
tron source [1]. We assumed a steady state for intra- and extracellu-
lar boron concentration, as previously reported data has shown
boron distribution throughout bodily ﬂuids in animals and humans
to occur in all tissues (except bone) at a concentration not signiﬁ-
cantly different from that in blood [33–36]. Moreover, we
maintained the cellular concentration of boric acid during irradiation
by keeping the cells in the medium they were incubated in.
To more accurately model parameters for future studies, we
compared the response of several cell lines, including U251MG—a
human glioma, and two normal cell lines. First, we chose the CHO-
K1 line previously used in our recent study on the accumulation of
new boron compounds, and then also examined the V79 cell line
(lung ﬁbroblasts that represent normal tissue cells and are generally
accepted in the literature as suitable models [1, 28, 32]).
Our cell survival data conﬁrmed the efﬁcacy of the accelerator
neutron source with the lithium target at BINP to produce a sufﬁ-
cient number of neutrons to initiate a boron neutron capture reac-
tion within and in proximity to tumor cells. The cell survival rate in
each cell line was inversely proportional to the boric acid concentra-
tion (Fig. 4), showing that the number of neutrons was sufﬁcient to
control further tumor cell growth; these results are comparable with
those obtained at the nuclear reactor using tumor cells incubated
with boric acid by Yamamoto et al. (2003) [1]. In our experiments,
the proton current was steadily ramped up to 3 mA to lessen the
irradiation time and was kept relatively stable during irradiation.
We calculated the radiobiological parameters based on the boron
concentration and observed the nature of the cell response to the
irradiation conditions. The cell survival curves were normalized to
the data for the cells irradiated without boron to remove fast
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Fig. 3. CF-assay results: 6-cm dishes with stained colonies of
each cell line 1–2 weeks after neutron irradiation. CHO-K1
(upper), V79 (middle) and U-251MG (lower) cells. The
boron concentration is 0, 10, 20 and 40 ppm (from left to
right).
Table 1. Surviving fractions of irradiated cells
Boron
concentration
(ppm)
10 20 40
SF V79 0.476 ± 0.160 0.346 ± 0.053 0.078 ± 0.015
U251MG 0.311 ± 0.061 0.131 ± 0.022 0.020 ± 0.010
CHO-K1 0.348 ± 0.069 0.058 ± 0.017 0.018 ± 0.005
Cell survival fractions (SFs) are presented as means ± SDs. All SFs signiﬁcantly
differed from controls (P < 0.01, ANOVA).
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neutron and gamma-ray components, with the assumption that all
detected neutrons were slowed down by the plexiglass to thermal
ones at the sample level and passed through the cells once. The
inﬂuence of prompt gamma-rays induced by the 10B (n,α) 7Li reac-
tion was also considered to be negligible for the following reasons.
First, only 16% of all energy released in the reaction is released
by gamma rays. Second, when alpha particles and lithium nuclei
that carry the bulk of the energy are characterized by a high decel-
eration rate and a small run in water or in biological tissues
(microns), the mean free path of gamma-rays with an energy of
478 keV exceeds the pathway of alpha particles and lithium nuclei
by more than an order of magnitude, which is comparable with
the sizes of the investigated samples; therefore, only a small part
of the energy of gamma-rays is released in the samples. The small
effect of prompt gamma-rays in the dose was conﬁrmed by calcu-
lations analogous to those described by Kandiev et al., 2011 [12].
Thus, in two cell lines (U251MG and CHO-K1), the survival
curves were linear, with β‘ = 0, reﬂecting the effect of a high-LET
radiation effect, typical for BNCT. In the V79 cell line, the pres-
ence of both α‘ and β‘ parameters could show the multicompo-
nent irradiation effect or speciﬁc response to BNCT, and the
character of the survival showed the cells were less susceptible to
our treatment.
The differential response between the cell lines could be due to
different radiosensitivity or differences in boron uptake. Generally,
it might be difﬁcult to exclude the inﬂuence of every possible factor,
as, regardless of our assumption, some percentage of neutrons may
keep higher energies while penetrating the samples, and temperature-
dependent neutron scattering cannot be perfectly predicted. Thus,
with respect to these unpredictable factors, our methodology to estab-
lish correct radiobiological parameters could be counted as limitations
of this study.
Longer irradiation times could also affect the overall results due
to additional inﬂuence from background dose. Therefore, in our
experiments, we normalized the responses of cells irradiated with
boron to control cells irradiated without boron to speciﬁcally
exclude the background component. The novelty of our report
required us to go above and beyond what would be normal irradi-
ation conditions to discover extreme parameters for both future
research and therapy. As technological developments merge with
data from multiple analyses, an almost guaranteed shorter irradi-
ation time will be the result as the neutron current increases. This
will minimize the background dose effect, and such long exposures
will not be typical of future studies.
In our study, we mainly focused on comparison between the
effect of the new source and previous data for clinically proven,
reactor-based experiments [2]. Therefore, at this stage of develop-
ment, a baseline comparison was focused on to the exclusion of the
cellular mechanisms of response to BNCT or variations in boron
uptake (which remain goals for future work). We showed that the
accelerator was effective in initial cell experiments and that its per-
formance as a neutron source was close to that of the reactor. For
future studies, it will be critical to study detailed parameters of both
mechanisms related to boron uptake in different cell lines/animal
models and cellular radiosensitivity.
In our experiments, the irradiation effect was obvious for the
cells, though the provided epithermal neutron ﬂuence still might
be insufﬁcient for clinical trials. In this regard, further improve-
ment of the accelerator, including stabilization of an increased (up
to 5 mA) proton current and development of a new lithium target
and neutron beam shaping assembly [13] is in progress. In our
study, as in many others, in vitro experiments play only an initial
role in evaluation of the method’s efﬁcacy. Animal experiments
with appropriate models more adequately and closely represent
clinical conditions and will be the main focus of our next set of
experiments.
CONCLUSION
We carried out an initial evaluation of an accelerator-based neutron
source for BNCT at BINP, using boric acid to create veriﬁed intra-
cellular boron concentrations that avoided compound accumulation
variations. Such variation depends on boron uptake mechanisms
and might differ in each cell line. We also proved the ability of the
irradiation source to provide sufﬁcient control over cell proliferation
after boron uptake. We believe that our study will bring more clarity
to ongoing in vitro experiments on neutron capture therapy and
help other researchers to advance accelerator-based BNCT into the
clinical phase.
Fig. 4. Cell survival curves depend on the boron
concentration in the samples. The data are presented as
means ± SDs. *P < 0.01 with respect to boron
concentration of 0 ppm (one-way ANOVA).
Table 2. Radiobiological parameters of irradiated cells
Cell line α′ β′ C10 (ppm)
V79 0.048 0.000390192 36.90
U251MG 0.103 0 22.39
CHO-K1 0.123 0 18.69
Parameters, such as α′ and β′ are presented as absolute numbers. C10 (in ppm)
represents the 10B concentration needed to eliminate 90% of tumor cells.
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